We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genosis | LSE:GNOS | London | Ordinary Share | GB00B0NVFD79 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.125 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:8013E
Genosis PLC
01 October 2007
FOR IMMEDIATE RELEASE 1 OCTOBER 2007
GENOSIS PLC
US PATENT OFFICE TO GRANT OVARIAN RESERVE PATENT
Genosis plc (AIM: GNOS), a UK company focusing on consumer products for
reproductive health, is pleased to announce that it has received notification of
allowance from the US Patent and Trademark Office for its patent application
covering urinary assays for Ovarian Reserve. The patent will provide protection
till 2023.
Genosis' Fertell products are protected by six patent families that have been
granted in both Europe and the US. Fertell is sold in the UK through Alliance
Boots and in the US through CVS and Longs Drugs as well as on the internet,
www.fertell.com.
Commenting on the announcement, Paul Bateman, CEO of Genosis said:
"We are delighted that this US patent application for our Ovarian Reserve assay
has been deemed both novel and inventive. This provides further strengthening
of Genosis' six patent families which offer broad protection for our unique male
and female fertility tests, Fertell - the world's only FDA cleared "at-home"
fertility test for couples."
- ENDS -
For further details, please contact:
Genosis Today on:
Paul Bateman, CEO / Jonathan Pockson, CFO Tel: +44 (0) 1483774050
Buchanan Communications
Lisa Baderoon / Rebecca Skye Dietrich Tel: +44 (0) 20 7466 5000
Evolution Securities
Tim Worlledge / Bobbie Hilliam Tel: +44 (0) 20 7071 4300
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDCCUDGGRI
1 Year Genosis Chart |
1 Month Genosis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
